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INTRODUCTION
Death from breast carcinoma in a premenopausal patient
has directed most physicians who are treating this disease
to review their cases and search for

8.

better means of

improving the cure rate and extending the survival time
of subsequent patients who present with this therapeutic
problem.
Advances in surgical technique, improved methods
of irradiation therapy, the relatively recent use of new
and better understood chemotherapeutic agents, and thera.peutic castra.tion have failed to change the mortality rate
in breast carcinoma since accurate records have been
available.

Breast cancer is the leading cause of carcinoma

in females.

The mortality rate for all females is 27 per

100,000, however, in the 45-50 age group this figure is
r

45 per 100,000 and there is a ltnear increase to 113 per
100,000 in the 75-80 a8e group_

(1)

The American Cancer

Society predicts 29,000 dea.ths and 67,000 new cases of
breast cancer in 1969.
This paper is underta.ken as a, review of the current
concepts in one method of treatment that ha,s long been
debated, frequently doubted, and usually supported or
condemmed with insufficient da,ta..
prophyla.ctic oophorectomy.

This trea.tment is
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REVIEW OF THE LITERATURE

An English surgeon named Cooper in 1832 was the first
to observe clinically and pa.thologica.lly that there wa.s an
increa.se in size of the tumor premenstrually and diminution
a,fter the menopause.

However, he appa.rently did not realize

the significance of these changes as he made no propose,l as
to the causal factors.

Thera,peutic ca,stration was being

done in the late Nineteenth Century and Schinzinger suggested
ca,stra,tion in menstrua,ting women who developed this tumor
before the ma,lignancy wa.s widespread.
performing this opera,tion.

He left no report of

This was left to Beatson who in

1896 reported improvement following castration in ca,ses of
inoperable breast ma,lignancy.

(26)

Numerous reports of

remissions appea,red in the literature a.s various practioners
began to use castration in their a.rmamentarium against recurrent disea,se, the so-called therapeutic ca,stra,tion.
Taylor in 1934 introduced the concept of radiation castra.tion a,s routine therapy B,ldlng with radical ma,stectomy in
uncomplica,ted breast ca,rcinoma in premenopause,l women.
His ba.sis of therapy wa,s that the decrea,sed ova.rian
a,ctivi ty would have an inhibitory influence on the development of meta,static deposits.

(23)

However, in 1939 he

reviewed his 17 patients treated by this method and could
show no significant difference in longevity from a. control
group.

In this review, Taylor introduced the term "pro-
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phyla,ctic castration. fI

(24)

Ada,ir in 1945 and Nathanson in 1951 both felt that the
resul ts both pro and con tha.t were being reported for prophyla,ctic ca.stra,tion were from valid, well controlled studies
but both concluded that the data they reviewed showed no
improvement in longevity when compared to therapeutic castration.

(9) (15)

J. Shelton Horsley in 1937 became disss.tisfied with

the poor results of radical ma,stectomy in young women
and began surgically removing both ovaries in women under
forty whenever a radical mastectomy was done f'or breast
malignanc1'.

He based his opera,tions on recent results of

experimental work rela,ting estrogens to mammary carcinoma.
and clinical results showing benefits of castra,tion in
advanced disease.

This series of patients has been followed

and more comment a.s to long term results will be ma.de
later in this paper.
Treves in 1957 reported. a series of 152 patients who
received prophylactic ca.stra.tion and compa.red these to a.
group of 2893 who were treated with ra,dical mastectomy.
Even though 84 of these patients were castra.ted with
X-ra;;, and 26 continued to menstruate, his sta.tistics still
showed increased longevity and a. longer interval before
recurrence.

In this article, Treves ste,tea that immediate

cessation of ovarian function is manda.tory, however, the

6

average length of time from mastectomy to castration was
8.7 months in X-ray ca,strated and 12.2 months in surgica.lly
castrated!

The degree of tumor involvement wa,s

a~so

much

gres,ter in the ca,strated group than in the controls.

(25)

Even with his rather impressive results this a,uthor in a
subsequent a,rticle in 1958 felt that ovarian ablation
should be reserved for patients with metastatic or recurrent disea,se.

(26)

other studies that have been reported include a, study
by Huck of 36 pa,tients treated by irradiation steriliza,tion
which showed no increasE\l5 yea:r survival over a, matched control group.

(7)

Siegert reported a difference of 16

months in onset of recurrence in radiation castra,ted women
in a series of 347 tree,ted compared with 260 controls.

(21)

Smi th alid Smith showed an increased 5 yea,r survival time
in 60 patients undergoing ca,stra,tion, however, 11 of these
were postmenopa.usal and the control group was not matched as
to a~e.

(22)

Patterson and Russell in a well designed and

controlled study to eva,luate effects of ra.diation ca,stra,tion
on breast carcinoma showed significant results at three'
yea:rs but not necessarily significant results at five yea:rs
which suggested to them tha,t although there was no clearout long term survival advantage, there was no real disa.dvantage.

(18)

M. P. Cole in 1964 reported follow-up

results on this series of Patterson and Russell.

In 367
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cases, 76 had recurrent or inoperable carcinomas.

In the

291 cases which were not far a.dvanced, she showed results
which although not statistically significant did show a.
definite trend towards increa.sed survival and increa.sed
interval to metastasis.

In this follow up, no mention

is made as to length of time between ma.stectomy and castration.

It should a.lso be mentioned that these cases were

all radia,tion ca.stration.

Even with this not favora,ble

factor, she wa,s able to show a' beneficial trend.

(2)

Rannaes in a series of 66 patients felt that although
their results were not necessaxily statistically significant, they believed that there was a trend toward
increa,sed survival and delay in recurrence of disease.

(19)

E. F. Lewison who has been a frequent contributor
to the literature feels that the decision between prophylactic and thera,peutic castra.tion is "The Doctor's Dilemma!"
He personally favors prophylactic caatration by surgical
means in women under age forty with stage II disea,se
and by irradiation in women over forty with stage II
disease.

For all other pa.tients he reserves castra,tion

only for therapeutic means.

(12)

He has never given his

personal series in the articles which were reviewed for

•

this paper and apparently bases his therapy primarily on
his own literature review in 1962 which has been widely
quoted by other authors.

His conclusion from this review
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compa,ring prophylactic and therapeutic castration wa,s that
there is a "well defined trend toward a, prolonged life
expectancy and an improved survival rate" in patients
treated with prophylactic castration.

(11)

Roseaberg and Uhlmann in 1959 reported their results
wi th 78 castra,ted and 122 non-castrated females, a,ll of
whom", had no signs of meta.stasis a.t the time of their
mastectomy.

Five year survival was used as a basis for

compaxing the efficacy of castra,tion.

Fifty-seven per-

cent of the castrated females and thirty-three per-cent of
the non-castrated group survived 5 years.

From these

observations, the a.uthors advocated prophyla.ctic ca,stration
in all women with caxcinoma of the breast who exhibited
signs of ovarian function.

(20)

Kennedy, Mielke; and Fortuny published in 1964 what
they felt to be the first studies comparing the relative
values of prophylactic ca.stration and therapeutic castration.
The senior author he.d written several previous articles
and in each had stressed that the stUdies which were being
followed dogmatically as guidelines to therapy were inadequa,te.

Using 2,908 cases of breast carcinoma"

they

culled 119 who had had a, prophyla.ctic castration and 177
who ha,d had a. therapeutic ca.stra.tion.

These groups were equa,l

in a.ll factors except tha.t there were more patients undergoing therapeutic castration who had more widespread disease.
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Therefore, two comparisons l'le:re

m~lde

in this study tone

between total groups and one between patients with equal
~olvement.

In comparing the groups with equal involve-

ment, these autho:rs concluded:
castration

del~ed

L

Tha:!; prophylactic

the onset of recurrent iisease.

2.

Tha,t the interval from recurrence to death ws,s less in:;
the prophylactic castrated group.

3.

That the interval

from initial tumor therapy to death was not sta.tiatically
different in the two groups with equal involvement.

(9)

Kennedy has used this da.ta in other axticles as a ba.sis

He has written that since

for his method of treatment.

ca,stration can serve as a, very' valuable guide to the hormonal responsiveness of a. tumor and, hence, responsiveness
to further hormonal ablation treatment, it should be done
only therapeutically.

(8)

Kennedy has also stressed tha.t

the term ffprophylacticl! ca,stration is a, misnomer a.s it
does not prevent recurrence of disea..se.

Hence, he favors

use of the terms Ifea.rlylf and nla.te t ! castra,tion when referring
to initia,l and recurrent therapy.
As previously mentioned in this pa,per, probs.bly the
first series of pa.tients receiving adequate follow-up
wa,s begun by Horsley in 1937.

(6)

In 1962, J. S. Horsley, III,

and G. W. Horsley reported follow-up on this series.
Sixty-eight cases of adenocarcinoma were treated and fcllowed.
Over;a.ll surviva.l rates at 5 and 10 years were 71% a.nd 47%
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respectively.

These studies did not have a control group

and 17 patients received X-ray therapy.
Roar Nissen-Meyer reported in 1967 the results of
breast cancer treatment at the

No~vegian

in two different series of patients.

Radium Hospital

T'.ae first group was

treated from 1932 to 1951 by radical mastectomy and postoperative radiation.

The second series was tree,ted from

1957 to 1967 by the same methods with the addition of prophylactic castra,tion.

A 59% survival ra.te wa.s obtained in

the first series and a 72% rate in the second series.
Meyer wisely analyzed the survival curves and found that
the first four years showed a divergency of the surviva.l
rate curves in favor of the castrated group but after five years
the curves converged.

He concluded tha,t prophylactic castra.-

tion did not change the overall survival ra,te but did
prolong surviva,l time.

He also did steroid excretion

studies on his patients and found that the ovaries

ma~

continue to produce hormones for up to ten yeaxs after tIle
menopause.

Also noted in this series was no difference

in the survival of pa,tients ca,strated by surgery or by
irradiation.

(16)
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STUDIES OF HORMONE RELATIONSHIPS
It is not \'1i thin the scope of this pa,per to extensively
review the literature concerned solely with hormone studies
which do not ha.ve clinical trials of thera.py.
In 1919 Loeb reported the prevention of mammary cancer
in fema.1e mice of e. special strain by castra,tion before the
age of six months.
report the

(13)

c~cinogenic

Lacassag-.ae was the first to
effect of estrogens on breasts of

special strains of mice.

(10)

It has been argued that

these mice are specially inbred and '91i11 develop carcinoma.
even if left a.1one and also, the doses of estrogens used
to produce brea.st tumors were astronomical.

Investiga.tors

have been unable to produce carginogenic changes in monkeys
with estrogenic compounds.

(28)

There have been no prospective studies on this problem
in humans, however, one notes that with the marked increase

in estrogen usage in the pa.st thirty yea.rs there has been
only one type of carcinoma. that ha.s had an increase in
incidence, that of breast carcinoma in,;.m.all.e.s trea.ted with
estrogens for prosta.tic carcinoma.

(17)

Many studies have

a.ctua.l1y shown a Itprotective effect" of estrogen therapy,
particularly in osteoporotic females who have shown less
than the predicted number of cancers
estrogen therapy.

(14)

fol1owL~g

prolonged

There is little doubt, however,
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tha,t hormone therapy does promote the growth of cancer of
the breast alrea,dy present.

(29)
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CASE STUDIES
As a paxt of this thesis, the cases of bres.st ca.rcinoma treated by ra.dical ma.stectomy and prophylactic
oophorectomy at the University of Nebraska., Cla.rkson
~.[emorial

and Methodist Hospi ta.ls were tabulated for a.

nationwide study by Dr. Wilson of the University of Texas
M:edica,l School.

This da.ta. was taken from the medical

records and is presented below.

All pa.tients were men-

struating at the time of oophorectomy.

One pa.tient ha.d

duct cell carcinoma, the rema.inder being a.denocarcinoma.
All tumors were less than four centimeters in diameter.

DATE OF

AXILLARY

DATE OF

MASTECTOMY

NODES

OOPHORECT01fi

5/12/61
6/20/58

+

-

3/31151

+

9/3/59
2/16/54
1/28159
12/13/66
2/8/68

+
+
+

+
Numbers in (

6/26/61
6/20/58

9/29/57
2/22/60
3/12/54
2110/59
1117/67
2/26/68

SURVIVAL STATUS RECURRENCE

10/3/68
Alive 3/31/69
Dec'd 11l21/59

Alive

NO (;~O)
NO

(40)

Alive

9j12/68

YES (4jl
YES (47)

Decfd

3/4/59

YES (43)

Dectd

YES

Alive

3/28/63
4/1/69

Alive

llj-q/68

(39)
NO (44)
NO (47)

) incicate age a,t mastectomy.

From these few cases one can readily see how important
it is to pool the case material from many institutions
so as to give physicians an answer in a rela.tively short
time.
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DISCUSSION
In reviewing the

a~ticles

on prophylactic versus

therapeutic oophorectomy one is impressed by most writers'
pleas for good prospective studies on this perplexing
problem.

TWo studies are currently in progress, the

Surgical Breast Adjuvant Study and theUniversity of Texa.s
l,'fedical School Study.

To be of significant va,lue these

will need to be very long term studies as is well stressed
in recent literature the continuing morta,lity after the
usua,l five or ten year studies.
One aspect of prophyla,ctic ca,stration that is generally a.greed upon is the time of oophorectomy.

It should

be done a.s soon s,fter the radica.l mastectomy as the patient r s
condi tion will a,llow.

G. W. Horsley has in the past per-

formed the oophorectomy while an assistant wa.s closing the
ma.stectomy incision.

(5)

This is certainly fea,sible if

the patient's condition is stable and

m~

even carry a. lesser

morbidity with only one anesthetic and post-opera,tive
period.
There is a principle of gynecological surgery that
one should almost always remove the uterus when performing a. bila.teral oophorectomy.
which stressed this pOint.

Only one

(27)

a~ticle

was found

A personal communica.tion

with members of the Gynecology Staff of the University of

15

Nebraska offered a€reement and two reasons:

1.

This

removes with little added morbidity and no added mortality
a now useless and frequent neoplasm producing organ.
2.

If estrogen chemotherapy is given to the patient at

a later date, how will one man8€e the troublesome bleeding
which will occur?

Whether a hysterectomy is performed

is presently left up to the surgeon performing the oophorectomy.

If he feels comfortable in performing a.

hyster~

ectomy and if he feels there will be no increa,sed morbidity, it should probably be done.
Whether irradiation castration is as effective a,s surgical
castration is certainly debata.ble.

The more recent a.rticles

have stressed that all of their patients ha.ve stopped menstruating, however, there is always a period of time
following irradia,tion that the ova.ries continue to function
and some patients will menstruate for severa,l months.
Therefore, it would seem tha,t if one desires immediate
cessation of ovarian function, surgival ca,stration is the
method of choice.
Some authors have discussed the psychological aspects
of castrating

Iii,

young female.

These certainly are impor-

tant and should not be forgotten in the conversations
between the physician and the patient preopera.tively and
during follow-up.

There should be very few, if any,

instances where if prophylactic oophorectomy would be of
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benef'i t i t would be deferred beca.use of the patient f s
psychological make-up.
The University of Nebraska Hospital is quite active
in reappraising the methods of' treating bres.at cancer.
We

a~e

study.

participating in the Surgical Breast Adjuvant
In

ea~ly

1967 prophyla,ctic ca,stration was not

being recommended by some members of' the Department of
Oncology since it was postulated by Dr. B. J. Kennedy
tha.t if a prophyla,ctic castrs.tion is performed it will be
difficult to tell if the breast tumor is hormonally
dependent.

Dr. Kennedy also believes that if one

compa~es

prophylactic with therapeutic castration, there is no
improvement in total surviva.l time.

Some members of

the University's Surgery and Oncology Departments now feel
that there is a delay in recurrence if surgical prophylactic castration is performed and survival time can be
increased

if chemotherapy is

currence.

Because of the Universityts involvement with

sta~ted

at the time of re-

the Breast Adjuvant Program, each premenopausal patient
wi th carcinoma of the bres.st is given a prophyla.ctic
castration according to instructions from the Study headquarters at Rosewell

Pa~k

Hospital, Buffalo, New York.

This method is used so that no bias is shown as to which
premenopausa.l patient will be castrated.

This is a more
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accura.te method in order to compa.re the effects of prophyla,ctic oophorectomy.
No matter what the outcome of future studies on
breast cancer, one must always keep the paramount thought
in mind that a high degree of suspicion and ea.rly dia,gnosis
still a£fords the best chance of cure in this disease.
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